Transcode Therapeutics, Inc. financial data

Symbol
RNAZ on Nasdaq
Industry
Pharmaceutical Preparations
Location
6 Liberty Square, #2382, Boston, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 163 % -1.19%
Debt-to-equity 130 % -2.58%
Return On Equity -597 % -7.24%
Return On Assets -260 % -8.83%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.3M shares +752%
Common Stock, Shares, Outstanding 7.27M shares +272%
Entity Public Float 4.4M USD -60%
Common Stock, Value, Issued 727 USD +273%
Weighted Average Number of Shares Outstanding, Basic 7.05M shares +23023%
Weighted Average Number of Shares Outstanding, Diluted 7.05M shares +23023%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.5M USD +2.29%
General and Administrative Expense 6.26M USD -31.7%
Operating Income (Loss) -17.8M USD +12.9%
Nonoperating Income (Expense) -94.4K USD -105%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -17.9M USD +3.64%
Earnings Per Share, Basic 296 USD/shares +99.5%
Earnings Per Share, Diluted 296 USD/shares +99.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.35M USD -6.1%
Assets, Current 4.39M USD -10.4%
Property, Plant and Equipment, Net 64.6K USD -63.9%
Operating Lease, Right-of-Use Asset 262K USD -62.5%
Assets 4.82M USD -18%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 3.5M USD -0.6%
Operating Lease, Liability, Noncurrent 38.3K USD
Liabilities 3.5M USD -7.57%
Retained Earnings (Accumulated Deficit) -54.9M USD -48.4%
Stockholders' Equity Attributable to Parent 1.32M USD -36.8%
Liabilities and Equity 4.82M USD -18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.94M USD +12.8%
Net Cash Provided by (Used in) Financing Activities 6.09M USD +416%
Net Cash Provided by (Used in) Investing Activities -3.84K USD +70.3%
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 7.27M shares +272%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.15M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.35M USD -6.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.65K USD -31.9%
Deferred Tax Assets, Valuation Allowance 12.7M USD +76.9%
Deferred Tax Assets, Gross 12.7M USD +76.9%
Operating Lease, Liability 227K USD -65.7%
Depreciation 32.2K USD +8.52%
Payments to Acquire Property, Plant, and Equipment 3.84K USD -70.3%
Lessee, Operating Lease, Liability, to be Paid 230K USD -66.4%
Property, Plant and Equipment, Gross 392K USD +3.43%
Operating Lease, Liability, Current 227K USD -42.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD -91.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.07K USD -85.5%
Deferred Tax Assets, Operating Loss Carryforwards 5.88M USD +71.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 353K USD
Operating Lease, Payments 407K USD -18.9%
Additional Paid in Capital 56.3M USD +43.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 127K USD +10.9%
Share-based Payment Arrangement, Expense 198K USD +25.1%
Interest Expense 4.48K USD -42.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%